RAB Symposium 2018
2nd Symposium on Regulatory Autoantibodies Targeting G-Protein-Coupled Receptors
-
Lübeck, September 28-30, 2018
GPCRs are involved in a variety of physiological and pathophysiological processes. So far, much effort has been made on anti-GPCR drug discovery with a focus on the development of small molecules and monoclonal antibodies for the treatment of cancer, infection, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies against GPCRs were identified in various diseases associated with pathogenesis, uncovering a potential new field of therapeutic intervention. Thus, the aim of this symposium is to combine the current knowledge about the role of GPCRs in different pathologies, their mode of action and state-of-the-art research techniques to identify common fundamental pathways that can be transferred to other disease entities with similar manifestations.
Prof. Dr. Gabriela Riemekasten
| 16:30 p.m. | Registration |
| 17:45 p.m. | Welcome and opening lectures Welcome note by the Symposium´s Chair Welcome note by the dean of the senate commitee in medicine (University Lübeck) The Mosaik and Kaleidoskope of Autoimmunity Network-based analysis reveals signatures of IgG autoantibodies targeting G protein-coupled receptors in health and disease |
| 19:00 p.m. | Get-together |
| 17:00 p.m. | Closing |
| 09:00 a.m. |
Anti-GPCR ab: advantages, pitfalls and problem in the diagnosis Functional ab causing psychiatric manifestations: Lessons need to be learned Patterns of 31 new autoantibodies against G protein-coupled receptors and growth factors Talks from selected abstracts |
| 11:00 a.m. | Are anti-GPCR ab pathogenic? Diagnostics of beta-adrenergic receptor autoantibodies in chronic heart failure Novel targets in the diagnosis of autoimmune and non-autoimmune diseases Anti-AT1R ab and autoimmunity to GPCR as cause or contributor to skin fibrosis and interstitial lung disease Monoclonal anti-AT1R ab from a SSc mouse model: evaluation of their functions Transfer of PBMC from SSc patients to immunodeficient mice leads to the production of autoantibodies against AT1R and ETAR Talks from selected abstracts |
| 13:30 p.m. | Poster Session Transfer of PBMC from SSc patients to immunodeficient mice leads to the production of autoantibodies against AT1R and ETAR (P01) ß1-adrenergic receptor autoantibody levels are higher in patients with Graves’ hyperthyroidism than in matched healthy controls and decrease after anti-thyroid treatment (P02) Sialylated autoantigen-reactive IgG antibodies attenuate disease development in mouse models of lupus nephritis and rheumatoid arthritis (P03) Autoantibodies targeting G-protein coupled receptors in RA and SLE (P04) Identification and characterization of cytomegalovirus-specific CD8+ T cells in systemic sclerosis (P05) Autoantibodies targeting complement receptors 3a and 5a are decreased in ANCA-associated vasculitis (P06) Impact of regulatory (auto-)antibodies against G-protein-coupled receptors on blood pressure in women ten years after early-onset preeclampsia (P07) Organotropism of anti-CXCR3/4- and anti-ETAR/-AT1R-mediated leukocyte migration in inflammatory and autoimmune disease (P08) Autoantibodies targeting muscarinic acetylcholine receptors: implications on fatigue in systemic sclerosis (P09) Role of anti-alpha-adrenoceptor autoantibodies and leukocytic alpha-adrenoceptors in primary Raynaud’s phenomenon (P10) Autoantibodies in serum of systemic scleroderma patients: peptide-based epitope mapping indicates increased binding to cytoplasmic domains of CXCR3 (P11) Detection and functional characterization of angiotensin receptor Type 1 autoantibodies: establishment and clinical translation (P12) Inflamed tissue contributes to the emergence of auto-reactivity in granulomatosis with polyangiitis (P13) Patterns of 31 new autoantibodies against G protein-coupled receptors and growth factors (P14) New insights into the diagnostics of autoantibodies against G-protein receptors – pitfalls in the autoantibody detection (P15) Network-based analysis reveals signatures of IgG autoantibodies targeting G protein-coupled receptors in healthy and diseases (P16) |
| 14:30 p.m. | Signaling of anti-GPCR ab: can we identify novel targets? Signaling and GPCR biology using cell models Lessons from dermatology: Anti-Dsg1/3 und anti-BP180-induced signaling Role of antibodies against PAR-1 and PAR-2 in cancer in the kidney transplant recipients Sialylated autoantigen-reactive IgG antibodies attenuate disease development in mouse models of lupus nephritis and rheumatoid arthritis Autoantibodies targeting complement receptors 3a and 5a are decreased in ANCA-associated vasculitis Impact of regulatory (auto-)antibodies against G-protein-coupled receptors on blood pressure in women ten years after early-onset preeclampsia Talks from selected abstracts |
| 16:30p.m. | Anti-GPCR ab as marker for diseases and therapeutic responses Antibodies against complement receptors: impact in pathophysiology? Anti-GPCR ab in atherosclerosis Immunoadsorption in Vascular Dementia - a novel approach to Alzheimer´s Disease? First results of the prospective ETiCS: inflammation rather than ischemia triggers the development of cardiac GPCR-autoantibodies Talks from selected abstracts |
| 18:30 p.m. | Closing |
| 09:00 a.m. | How to target effects of functional antibodies Chronic Fatigue-Syndrom and Apherese The aptamer BC 007 completely neutralizes agonistic autoantibodies directed against ß1-adrenoceptors: Results of a phase 1 trial Agonistic antibody disesaes = Autoimmune diseases ? - From bench to bedside Detection and functional characterization of angiotensin receptor Type 1 autoantibodies: establishment and clinical translation Talks from selected abstracts |
| 10:50 a.m. | Summary and Closing Remarks Challenges in the research of anti-GPCR ab Closing Remarks |